- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03839355
Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation (ARISTA)
February 23, 2021 updated by: Malini Madhavan, Mayo Clinic
Randomized Trial of Apixaban vs Dose Adjusted Warfarin in Reducing Rate of Cognitive Function Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Non-valvular Atrial Fibrillation Patients With CHA2DS2-VaSc Score = 2
The investigators' central hypothesis is that in patients with atrial fibrillation, anticoagulation with Apixaban reduces the rate of decline in cognitive function, when compared to Warfarin.
The investigators also hypothesize that Apixaban reduces cognitive decline by reducing the rate of new cerebral infarction and cerebral microbleeds detected by cerebral MRI compared to warfarin.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Non-valvular Atrial Fibrillation
- CHA2DS2-VASc Score > or = to 2
- Never been treated with Apixaban (Eliquis) or prior treatment of < 1 month
- Candidate for oral anticoagulation as assessed by a treating physician
Exclusion Criteria:
- Valvular Atrial Fibrillation (Rheumatic valve disease,Moderate or greater mitral stenosis,Mechanical cardiac valve)
- Active Bleeding
- Prior treatment with Apixaban >1 month
- Recent stroke within 7 days
- Dementia
- Implanted devices not compatible with MRI/any cardiac implanted device
- Claustrophobia
- Active alcohol/drug abuse
- Life expectancy < 1 year
- Taking asprin with >100mg doses
- Known hypersensitivity to warfarin or Apixaban
- Severe renal insufficiency
- Prior severe bleeding (Intracranial bleeding (subdural, subarachnoid, intraparenchymal bleeding),GI bleed requiring transfusion,Bleeding from other sites requiring transfusion)
- Psychosocial reasons that make study participation impractical
- Currently enrolled in another IND or IDE trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints
- Co-morbid condition(s) that could limit the subject's ability to participate in the trial or to comply with follow-up requirements, or that could impact the scientific integrity of the study.
- Prisoners or subjects who are involuntarily incarcerated
- Subjects who are compulsorily detained for treatment of either psychiatric or physical illness
- Current or expected systemic treatment with strong dual inhibitors of CYP3A4 and P-gp (Any one of rifampin, carbamazepine, phenytoin, St. John's Wort, ketoconazole, itraconazole, ritonavir, clarithromycin)
- Need for dual anti-platelet therapy with aspirin and another agent such as thienopyridine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Eliquis
|
Dosage either 5mg or 2.5mg for 2 years
Other Names:
|
ACTIVE_COMPARATOR: Warfarin
|
Dosage assessed by your treating physician for 2 years
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Standardized Neurocognitive Function Score
Time Frame: Baseline, Year 1, Year 2
|
Assess the change in cognitive function using standardized neurocognitive assessment.
|
Baseline, Year 1, Year 2
|
MRI Evidence of Silent Cerebral Infarct
Time Frame: Baseline, Year 2
|
Magnetic Resonance Imagining of the brain to assess the development of new silent cerebral infarcts.
|
Baseline, Year 2
|
MRI Evidence of New Cerebral Micro-bleeds
Time Frame: Baseline, Year 2
|
Magnetic Resonance Imagining of the brain to assess the development of new cerebral micro-bleeds
|
Baseline, Year 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Malini Madhavan, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 19, 2018
Primary Completion (ACTUAL)
December 15, 2020
Study Completion (ACTUAL)
December 15, 2020
Study Registration Dates
First Submitted
February 11, 2019
First Submitted That Met QC Criteria
February 13, 2019
First Posted (ACTUAL)
February 15, 2019
Study Record Updates
Last Update Posted (ACTUAL)
March 16, 2021
Last Update Submitted That Met QC Criteria
February 23, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Arrhythmias, Cardiac
- Brain Ischemia
- Infarction
- Stroke
- Brain Infarction
- Atrial Fibrillation
- Cerebral Infarction
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Apixaban
- Warfarin
Other Study ID Numbers
- 17-010544
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Apixaban
-
PfizerBristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompleted
-
Assistance Publique - Hôpitaux de ParisBristol-Myers SquibbActive, not recruitingCancer-associated ThrombosisFrance, Spain, Netherlands, Belgium, Austria, Greece, Switzerland, Canada, Italy, Poland, United Kingdom
-
The Affiliated Hospital of Qingdao UniversityCompleted
-
Portola PharmaceuticalsCompleted
-
Baim Institute for Clinical ResearchBristol-Myers SquibbCompletedAtrial FibrillationUnited States
-
Doasense GmbHActive, not recruitingAnticoagulant TherapyGermany
-
University Hospital, GenevaSunnybrook Health Sciences CentreNot yet recruitingDeep Vein Thrombosis
-
Universitaire Ziekenhuizen KU LeuvenRecruitingAnticoagulation | Short Bowel SyndromeBelgium
-
Artivion Inc.Duke Clinical Research InstituteTerminatedAortic Valve Stenosis | Aortic Valve Disease | Aortic Valve FailureUnited States